Synthetic oligonucleotides, their complexes and conjugates with other biomolecules represent valuable research tools and therapeutic agents. In spite of growing applications in basic research and clinical science, only few studies have addressed the issue of such compounds' stability in biological media. Herein, we studied the stability of two therapeutically relevant oligonucleotide probes in simulated biofluids; the 21 nucleotide-long DNA/locked nucleic acid oligonucleotide ON targeted toward cancer-associated BRAF V600E mutation, and a longer DNA analog (TTC) originating from BRAF gene. We found that stability of peptide–oligonucleotide conjugates (POCs) in human serum (HS) was superior compared with the naked or complexed 21mer oligonucleotide, whereas stability of POCs in simulated gastric juice (GJ) was dependent on the peptide sequence. Addition of pepstatin A in general increased the stability of oligonucleotides after 24 h digestion in HS and simulated GJ. Similarly, complexation with optimal amounts of histone proteins was found to rescue oligonucleotide stability after 24 h digestion in hydrochloric acid.
Get full access to this article
View all access options for this article.
References
1.
WangS, AllenN, VickersTA, RevenkoAS, SunH, LiangXH and CrookeST. (2018). Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides. Nucleic Acids Res, 46:3579–3594.
2.
VeltropM, van VlietL, HulskerM, ClaassensJ, BrouwersC, BreukelC, van der KaaJ, LinssenMM, den DunnenJT, et al. (2018). A dystrophic Duchenne mouse model for testing human antisense oligonucleotides. PLoS One, 13:e0193289.
3.
PatonDM. (2017). Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy. Drugs Today, 53:327–337.
4.
GearyRS, NorrisD, YuR and BennettCF. (2015). Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev, 87:46–51.
5.
PrakashTP. (2011). An overview of sugar‐modified oligonucleotides for antisense therapeutics. Chem Biodivers, 8:1616–1641.
6.
ChanJHP, LimS and WongWSF. (2006). Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol, 33:533–540.
7.
KoolET. (2002). Replacing the nucleobases in DNA with designer molecules. Acc Chem Res, 35:936–943.
8.
XuC and WangJ. (2015). Delivery systems for siRNA drug development in cancer therapy. Asian J Pharm Sci, 10:1–12.
9.
AbesR, MoultonHM, ClairP, YangST, AbesS, MelikovK, PrevotP, YoungbloodDS, IversenPL, ChernomordikLV and LebleuB. (2008). Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure–activity studies. Nucleic Acids Res, 36:6343–6354.
10.
TaskovaM, MantsiouA and AstakhovaK. (2017). Synthetic nucleic acid analogues in gene therapy: an update for peptide-oligonucleotide conjugates. ChemBioChem, 18:1671–1682.
11.
PrakashTP, GrahamMJ, YuJ, CartyR, LowA, ChappellA, SchmidtK, ZhaoC, AghajanM, et al. (2014). Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res, 42:8796–8807.
12.
TaskovaM, MadsenCS, JensenKJ, HansenLH, VesterB and AstakhovaK. (2017). Antisense oligonucleotides internally labeled with peptides show improved target recognition and stability to enzymatic degradation. Bioconjug Chem, 28:768–774.
13.
LiuY, ZhangY, GuoH, WuW, DongP and LiangX. (2016). Accelerated digestion of nucleic acids by pepsin from the stomach of chicken. Br Poult Sci, 57:674–681.
14.
LiuY, ZhangY, DongP, AnR, XueC, GeY, WeiL and LiangX. (2015). Digestion of nucleic acids starts in the stomach. Sci Rep, 5:11936.
15.
AttarwalaH, HanM, KimJ and AmijiM. (2018). Oral nucleic acid therapy using multicompartmental delivery systems. Wiley Interdiscip Rev Nanomater Nanobiotechnol, 10:1–20.
16.
ForbesDC and PeppasNA. (2012). Oral delivery of small RNA and DNA. J Control Release, 162:438–445.
17.
CarverJD andAllan WalkerW. (1995). The role of nucleotides in human nutrition. J Nutr Biochem, 6:58–72.
18.
Tahmasebi-KohyaniA, KeyvanshokoohS, NematollahiA, MahmoudiN and Pasha-ZanoosiH. (2011). Dietary administration of nucleotides to enhance growth, humoral immune responses, and disease resistance of the rainbow trout (Oncorhynchus mykiss) fingerlings. Fish Shellfish Immunol, 30:189–193.
19.
McAllanAB. (1980). The degradation of nucleic acids in, and the removal of breakdown products from the small intestines of steers. Br J Nutr, 44:99–112.
20.
SteinCA and CastanottoD. (2017). FDA-approved oligonucleotide therapies in 2017. Mol Ther, 25:1069–1075.
21.
LiuY, ZhangY, JiangW, WangJ, PanX, WuW, CaoM, DongP and LiangX. (2017). Nucleic acids digestion by enzymes in the stomach of snakehead (Channa argus) and banded grouper (Epinephelus awoara). Fish Physiol Biochem, 43:127–136.
22.
VickersTA and CrookeST. (2016). Development of a quantitative BRET affinity assay for nucleic acid-protein interactions. PLoS One, 11:e0161930.
23.
Mihic-ProbstD, PerrenA, SchmidS, SaremaslaniP, KomminothP and HeitzPU. (2004). Absence of BRAF gene mutations differentiates Spitz nevi from malignant melanoma. Anticancer Res, 24:2415–2418.
24.
LochmannD, JaukE and ZimmerA. (2004). Drug delivery of oligonucleotides by peptides. Eur J Pharm Biopharm, 58:237–251.
25.
TonchevaV, WolfertMA, DashPR, OupickyD, UlbrichK, SeymourLW and SchachtEH. (1998). Novel vectors for gene delivery formed by self-assembly of DNA with poly(l-lysine) grafted with hydrophilic polymers. Biochim Biophys Acta, 1380:354–368.
26.
Mariño-RamírezL, LevineKM, MoralesM, ZhangS, MorelandRT, BaxevanisAD and LandsmanD. (2011). The Histone Database: an integrated resource for histones and histone fold-containing proteins. Database, 2011:bar048.
27.
Vitravene Study Group. (2002). A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol, 133:467–474.
28.
van DeutekomJC, JansonAA, GinjaarIB, FrankhuizenWS, Aartsma-RusA, Bremmer-BoutM, den DunnenJT, KoopK, van der KooiAJ, et al. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med, 357:2677–2686.
29.
GoemansNM, TuliniusM, van den AkkerJT, BurmBE, EkhartPF, HeuvelmansN, HollingT, JansonAA, PlatenburgGJ, et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med, 364:1513–1522.
30.
TasfaoutH, BuonoS, GuoS, KretzC, MessaddeqN, BootenS, GreenleeS, MoniaBP, CowlingBS and LaporteJ. (2017). Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice. Nat Commun, 8:15661.
31.
SpillantiniMG, PanconesiA, Del BiancoPL and SicuteriF. (1986). Enkephalinase and angiotensin converting enzyme activities in human venous and arterial plasma. Neuropeptides, 8:111–117.
32.
SpillantiniMG, SicuteriF, SalmonS and MalfroyB. (1990). Characterization of endopeptidase 3.4.24.11 (‘enkephalinase’) activity in human plasma and cerebrospinal fluid. Biochem Pharmacol, 39:1353–1356.
33.
YiJ, KimC and GelfandCA. (2007). Inhibition of intrinsic proteolytic activities moderates preanalytical variability and instability of human plasma. J Proteome Res, 6:1768–1781.
34.
ShawJP, KentK, BirdJ, FishbackJ and FroehlerB. (1991). Modified deoxyoligonucleotides stable to exonuclease degradation in serum. Nucleic Acids Res, 19:747–750.
35.
SisavathN, LeclercqL, Le SauxT, OukacineF and CottetH. (2013). Study of interactions between oppositely charged dendrigraft poly-L-lysine and human serum albumin by continuous frontal analysis capillary electrophoresis and fluorescence spectroscopy. J Chromatogr A, 1289:127–132.
36.
ChuBC and OrgelLE. (1992). The stability of different forms of double-stranded decoy DNA in serum and nuclear extracts. Nucleic Acids Res, 20:5857–5858.
37.
DemidovVV, PotamanVN, Frank-KamenetskiiMD, EgholmM, BuchardO, SönnichsenSH and NielsenPE. (1994). Stability of peptide nucleic acids in human serum and cellular extracts. Biochem Pharmacol, 48:1310–1313.
38.
ZwiersA, CrusiusB, PalsG, DonkerAJ, MeuwissenSG and ten KateRW. (1990). Human pepsinogen A isozymogen patterns in serum and gastric mucosa. Gastroenterology, 99:1576–1580.
39.
SannyCG, HartsuckJA and TangJJ. (1975). Conversion of Pepsinogen to Pepsin. Further evidence for intramolecular and pepsin-catalyzed activation. J Biol Chem, 250:2635–2639.
40.
Cornish-BowdenAJ and KnowlesJR. (1969). The pH-dependence of pepsin-catalysed reactions. Biochem J, 113:369–375.
41.
MalamudD and DrysdaleJW. (1978). Isoelectric points of proteins: a table. Anal Biochem, 86:620–647.
42.
AndreevaNS and JamesMN. (1991). Why does pepsin have a negative charge at very low pH? An analysis of conserved charged residues in aspartic proteinases. Adv Exp Med Biol, 306:39–45.
43.
ZhangY, LiC, LiuY, WangX, DongP and LiangX. (2016). Mechanism of extraordinary DNA digestion by pepsin. Biochem Biophys Res Commun, 472:101–107.
KamakakaRT and BigginsS. (2005). Histone variants: deviants?. Genes Dev, 19:295–310.
46.
StenzelS, BohrischJ and MeyerMJ. (2014). Enhancing ssDNA stability at acidic pH by encapsulation for the usage as DNA marking system. Appl Polym Sci, 132:1–7.
47.
LeProustEM, PeckBJ, SpirinK, McCuenHB, MooreB, NamsaraevE and CaruthersMH. (2010). Synthesis of high-quality libraries of long (150mer) oligonucleotides by a novel depurination controlled process. Nucleic Acids Res, 38:2522–2540.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
